PCI Pharma Services to Invest $100 Million in New Hampshire Facility

PCI Pharma Services (PCI), a contract development and manufacturing organization (CDMO) and biopharma global outsourcing services provider, is expanding its aseptic fill-finish technology capabilities for liquids and sterile lyophilization, which is a manufacturing process commonly used for injectable and biologic therapies. The company is set to invest $100 million to build and upgrade the facilities at its Bedford, NH location.

Following PCI's acquisition of Lyophilization Services of New England, Inc. (LSNE) in December 2021, the expansion plan calls for a facility of more than 49,500 square feet. The facility will feature state-of-the-art technology, including an aseptic fill-finish line with a fully insulated containment system. It will also have two twin freeze dryers with automatic loading and unloading systems, with a capacity to complete 400 vials per minute on a sterile fill-finish line.

The facility will also work toward ensuring that the CDMO is ahead of the demand for integrated solutions for small and large molecules from clinical and commercial customers.

"We are excited to introduce our brand-new facility to our customers, which is part of our overall strategy to provide integrated end-to-end drug development, manufacturing, and packaging capabilities," says Salim Haffar, CEO of PCI Pharma Services. “By investing in these facilities, PCI intends to continue to develop new capabilities in complex formulations, aseptic fill-finish, and freeze-drying to meet the needs of our global customers as biologics continues to grow.”